Hangzhou Tigermed Consulting Co., Ltd Stock
Equities
300347
CNE100001KV8
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
59.11 CNY | -0.94% | +18.86% | +7.53% |
Apr. 25 | Hangzhou Tigermed Consulting’s Profit Down 59% in Q1 | MT |
Apr. 25 | Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the First Quarter Ended March 30, 2024 | CI |
Sales 2024 * | 8.2B 1.13B | Sales 2025 * | 9.92B 1.37B | Capitalization | 47.91B 6.62B |
---|---|---|---|---|---|
Net income 2024 * | 2.03B 281M | Net income 2025 * | 2.58B 357M | EV / Sales 2024 * | 5.23 x |
Net cash position 2024 * | 5.04B 696M | Net cash position 2025 * | 10.41B 1.44B | EV / Sales 2025 * | 3.78 x |
P/E ratio 2024 * |
29.4
x | P/E ratio 2025 * |
20
x | Employees | - |
Yield 2024 * |
0.77% | Yield 2025 * |
1.07% | Free-Float | 69.94% |
1 day | -0.94% | ||
1 week | +18.86% | ||
Current month | +11.21% | ||
1 month | +11.21% | ||
3 months | +36.48% | ||
6 months | -3.21% | ||
Current year | +7.53% |
Managers | Title | Age | Since |
---|---|---|---|
Xiao Chun Cao
CEO | Chief Executive Officer | 55 | 04-12-31 |
Hao Wu
PSD | President | 56 | 19-12-31 |
Xiao Ping Ye
CHM | Chairman | 61 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Xiao Chun Cao
CEO | Chief Executive Officer | 55 | 04-12-31 |
Bing Hui Zhang
CHM | Chairman | 61 | 20-04-27 |
Xiao Ping Ye
CHM | Chairman | 61 | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-30 | 59.11 | -0.94% | 10,940,130 |
24-04-29 | 59.67 | +3.41% | 23,805,780 |
24-04-26 | 57.7 | +8.85% | 30,450,980 |
24-04-25 | 53.01 | +0.78% | 13,788,770 |
24-04-24 | 52.6 | -0.92% | 16,332,140 |
End-of-day quote Shenzhen S.E., April 29, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.53% | 6.6B | |
+26.28% | 42.68B | |
-3.99% | 42.4B | |
+45.32% | 40.04B | |
-6.20% | 28.31B | |
+6.36% | 24.94B | |
-21.47% | 18.96B | |
+27.58% | 12.3B | |
-2.75% | 11.95B | |
-2.02% | 11.55B |
- Stock Market
- Equities
- 300347 Stock